Clinical Trials Logo

Cerebral Cavernous Malformations clinical trials

View clinical trials related to Cerebral Cavernous Malformations.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03467295 Recruiting - Clinical trials for Cerebral Cavernous Malformations

Treatments and Outcomes of Untreated Cerebral Cavernous Malformations in CHina.

TOUCH
Start date: January 1, 2018
Phase:
Study type: Observational

This nationwide multicenter prospective cohort study will collect the treatment information and outcomes of the patients with previously untreated cavernous malformations (U-CMs) in China (at least 2000 patients from 20 centers). The investigators aim to determine the effect of different treatments on long-term outcomes in patients with untreated cerebral cavernous malformations.

NCT ID: NCT01764529 Recruiting - Clinical trials for Cerebral Cavernous Malformations

Modifiers of Disease Severity in Cerebral Cavernous Malformations

Start date: April 27, 2010
Phase:
Study type: Observational [Patient Registry]

Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine. CCMs can bleed and cause strokes, seizures, and headaches. CCMs are often caused by an inherited gene mutation (alteration) in one of three CCM genes (CCM1, CCM2, or CCM3). There is a wide range of disease severity even among family members with this disease, though the natural history has not been clearly described for this particular population. This study will continue to enroll and follow participants with familial CCM to identify factors that influence CCM disease severity and progression, focusing on barriers to clinical trial preparedness. Our long-term goal is to identify measurable outcomes and robust biomarkers that will help select high-risk patients and help monitor drug response in future clinical trials. The specific goals of this study are to: - Identify factors that influence lesion progression to symptomatic hemorrhage and other outcomes, including quality of life; - Investigate the role of the gut microbiome and lesion burden in CCM disease, and - Identify blood biomarkers predictive of CCM disease severity and progression for clinical trials.